U.S. markets have recovered following 2022’s historic selloff, leading some to question what comes next. In this environment, we believe certain active approaches are better positioned to benefit than others.
Executive Managing Director and Sr. Portfolio Manager Brian Christiansen discusses the importance of candor and collaboration in a culture that promotes long-term thinking.
Recruit Holdings is transforming the world of work through wage transparency and providing life-changing opportunities for immigrants and refugees.
Our second annual stewardship report reflects our commitment to provide clients and other key stakeholders with transparency into our initiatives, actions, and the progress we made in 2022.
Our life sciences strategy looks to invest in promising life sciences companies that we believe are at the heart of a technological and scientific revolution in healthcare.
Executive Managing Partner
Executive Managing Director
Sands Capital (2016 - 2022)
Arlington, VA | Managing Partner
Enzymatics Inc. (2013 - 2015)
Beverly, MA | CEO
Stemgent Inc. (2008 - 2013)
Cambridge, MA | Founder, CEO
Upstate Inc. (2002 - 2004)
Charlottesville, VA | President
University of Virginia
MBA | Darden School
University of Surrey
Ian is a serial entrepreneur and has 20 years of experience starting and investing in life sciences technology businesses as an angel, venture and private equity investor. Ian has served in many roles as a founder, CEO, CFO, COO, chairman, director, and advisor to a number of privately-held Life Science product and service businesses. He has focused on the cell signaling, drug screening, genomics and sequencing, and cell culture and modification segments, at all stages of business development from initiation through profitability to trade sell. Prior to joining Sands Capital, Ian was the Chairman and CEO of Enzymatics Inc., founder and CEO of Stemgent, Inc., a stem and iPS cell life sciences tool, and President of Upstate Inc., a leading provider of cell signaling research products and services. Ian was also a founding investor in Firefly Bioworks and Genometry, both SCV investments. Ian has a degree in Chemical Engineering from University of Surrey and has a MBA from the Darden School at the University of Virginia.